Search results for "COVID-19"


 
Results 91 - 100 of about 462 for "COVID-19".
Sort by: Relevance | Newest | Oldest

ACP, Annals of Internal Medicine host ninth forum on COVID-19

A full recording of COVID-19 Forum IX: Management of Patients with Persistent Symptoms after COVID-19 is available for replay online.
https://immattersacp.org/weekly/archives/2022/05/31/4.htm
31 May 2022

New ACP living practice points, mortality data on COVID-19

The College offered recommendations on outpatient COVID-19 treatments. Three studies looked at shifts in mortality from COVID-19 at different times and places. An international study compared infections in health care workers with medical masks versus N95s.
https://immattersacp.org/weekly/archives/2022/11/29/2.htm
29 Nov 2022

New COVID-19 boosters authorized and recommended

The CDC has recommended the new formulations of the mRNA vaccines, targeted at the BA.4 and BA.5 lineages of the omicron variant, for adults and adolescents who last received a COVID-19 shot at least two months ago.
https://immattersacp.org/weekly/archives/2022/09/06/2.htm
6 Sep 2022

COVID-19 rebound occurs with or without antivirals, doesn't affect outcomes, studies find

Rebound of both COVID-19 symptoms and viral load was rare in untreated, unvaccinated outpatients, one study showed, while another found similar rates of viral rebound in patients treated with nirmatrelvir-ritonavir, molnupiravir, or neither antiviral.
https://immattersacp.org/weekly/archives/2023/02/21/2.htm
21 Feb 2023

New COVID-19 vaccine authorized; reviews analyze myocarditis, drug treatments

The FDA gave the Novavax COVID-19 vaccine emergency use authorization for adults. One recent review found lower myocarditis risk with the Pfizer-BioNTech vaccine than the Moderna vaccine, and another looked at the strength of evidence supporting COVID-19 drug treatments.
https://immattersacp.org/weekly/archives/2022/07/19/4.htm
19 Jul 2022

CDC and FDA weigh in on safety of bivalent vaccine; research examines COVID-19 sequelae, omicron variants

The CDC and FDA said an observed association of ischemic stroke with the Pfizer-BioNTech bivalent booster is very unlikely to represent a true clinical risk. New studies reported on symptoms a year after mild COVID-19 and estimated protection against the omicron variants.
https://immattersacp.org/weekly/archives/2023/01/24/2.htm
24 Jan 2023

Fourth vaccine dose 62% effective against severe COVID-19 in month after receipt

Retrospective data from Israel showed that in people ages 60 years and older, an additional booster dose of the Pfizer-BioNTech COVID-19 vaccine was 55% effective against symptomatic disease and 68% effective against hospitalization.
https://immattersacp.org/weekly/archives/2022/04/19/4.htm
19 Apr 2022

Frequency of COVID-19 rebound debated in research, ACP/Annals forum

Two letters reported on SARS-CoV-2 viral rebound among patients taking nirmatrelvir-ritonavir. The latest ACP and Annals of Internal Medicine forum brought experts together to discuss this and other clinical challenges in COVID-19 prevention and management on Wednesday, Sept. 7.
https://immattersacp.org/weekly/archives/2022/09/13/2.htm
13 Sep 2022

NJ licensure during COVID-19 offers example of how to meet workforce demand

Temporary licensure of out-of-state practitioners, along with telehealth waivers, may be a valuable, short-term solution to mitigating health care workforce shortages during public health emergencies, researchers said.
https://immattersacp.org/weekly/archives/2022/08/09/4.htm
9 Aug 2022

Latest COVID-19 research on VTE risk, treatment with metformin, ivermectin, fluvoxamine

Unvaccinated patients may have higher risk of venous thromboembolism (VTE) when mildly ill, one study found, while another showed no effect from metformin, ivermectin, or fluvoxamine. Research supported the safety of the mRNA vaccines, and the NIH updated its treatment guidelines.
https://immattersacp.org/weekly/archives/2022/08/23/4.htm
23 Aug 2022

Result Page: Prev   5   6   7   8   9   10   11   12   13   14   Next